LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...
A new study found that 53.5 percent of surveyed US college students reported experiencing at least one harm caused by someone else’s drinking, ranging from verbal abuse and physical confrontations to ...